{
  "model": "kimi-k2.5",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 2,
  "workspacePath": "workspaces/kimi-k2-5-tumor-vaccine-ici-run-2",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 40799,
  "agentCostUsd": 0.023249600000000002,
  "graderCostUsd": 0.015715,
  "totalCostUsd": 0.0389646,
  "agentUsage": {
    "promptTokens": 27256,
    "cachedTokens": 11150,
    "responseTokens": 4157,
    "thinkingTokens": 0,
    "totalTokens": 31413
  },
  "graderUsage": {
    "promptTokens": 4524,
    "cachedTokens": 0,
    "responseTokens": 386,
    "thinkingTokens": 171,
    "totalTokens": 5081
  },
  "totalUsage": {
    "promptTokens": 31780,
    "cachedTokens": 11150,
    "responseTokens": 4543,
    "thinkingTokens": 171,
    "totalTokens": 36494
  },
  "modelVersions": [
    "accounts/fireworks/models/kimi-k2p5"
  ],
  "agentFinalText": "## Completion Checklist\n\nAll required output files have been successfully written:\n\n- [x] `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\n- [x] `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\n- [x] `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\n- [x] `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Can intratumoral delivery of mRNA vaccines create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 checkpoint blockade therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy\",\n      \"label\": \"Mouse efficacy cohort\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice pooled across repeat experiments receiving combination therapy of intratumoral mRNA vaccine and anti-PD-L1.\"\n    },\n    {\n      \"id\": \"mouse-control\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls receiving vaccine only, ICI only, or vehicle.\"\n    },\n    {\n      \"id\": \"human-metastatic\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Retrospective cohort of metastatic patients receiving ICI treatment, analyzed by prior SARS-CoV-2 mRNA vaccination status.\"\n    },\n    {\n      \"id\": \"human-vaccinated\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Subgroup of metastatic patients with prior SARS-CoV-2 mRNA vaccination receiving ICI treatment.\"\n    },\n    {\n      \"id\": \"human-unvaccinated\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Subgroup of metastatic patients without prior SARS-CoV-2 mRNA vaccination receiving ICI treatment.\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n  ]\n}\n"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination.\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape.\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment.\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors.\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable.\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy.\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings.\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": false,
      "errors": [
        "Quote in C01 was not found verbatim in report: \"Type I interferon response score (normalized units) 3.1 vs 1.0 Marked induction after mRNA vaccination in tumors\"",
        "Quote in C02 was not found verbatim in report: \"Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3% Broader antigen display after intratumoral mRNA vaccination\"",
        "Quote in C02 was not found verbatim in report: \"Fraction of proteins represented in MHC-I peptidome 40.6% vs 20.6% Strong expansion of MHC-I-presented landscape\"",
        "Quote in C03 was not found verbatim in report: \"PD-L1 expression fold-change in tumor tissue 2.4x vs 1.0x Checkpoint axis became more targetable\"",
        "Quote in C04 was not found verbatim in report: \"Retrospective human survival comparison p-value p=0.01 Vaccinated subgroup had improved survival under ICI treatment\"",
        "Quote in C05 was not found verbatim in report: \"Intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x Increased immune infiltration with combination therapy\""
      ],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Type I interferon response score (normalized units) 3.1 vs 1.0 Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"Intratumoral mRNA vaccination creates broader antigen display by expanding the fraction of tumor proteins represented in the immunopeptidome.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome 62.3% vs 37.3% Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome 40.6% vs 20.6% Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue 2.4x vs 1.0x Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\",\n          \"line_ref\": \"L11\"\n        }\n      ],\n      \"caveat\": \"The combination effect was tested in murine models; translation to human tumors requires prospective validation.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Prior SARS-CoV-2 mRNA vaccination is associated with improved survival in metastatic patients receiving immune checkpoint inhibitor treatment.\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value p=0.01 Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n          \"line_ref\": \"L49\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; vaccination timing relative to ICI initiation varied across patients; tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"Combined intratumoral mRNA vaccination and checkpoint blockade increases CD8+ T-cell infiltration in tumors.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change 1.8x vs 1.0x Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    }\n  ]\n}\n"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"COVID-19 mRNA vaccines may enhance cancer immunotherapy by priming tumors to respond better to checkpoint inhibitors.\",\n  \"plain_language_summary\": \"Immune checkpoint inhibitors are drugs that help the immune system fight cancer, but many tumors do not respond well because they hide from immune cells. This study tested whether mRNA vaccines, similar to those used for COVID-19, could make tumors more visible to the immune system. In laboratory mice with tumors, injecting mRNA directly into tumors created an inflammatory environment that improved the effectiveness of checkpoint inhibitor drugs. The researchers also looked back at medical records of cancer patients who received immunotherapy and found that those who had previously received COVID-19 mRNA vaccines had better survival outcomes. The mRNA treatment worked by increasing the display of tumor proteins on immune cells and raising levels of PD-L1, a target for checkpoint drugs. While promising, this research was done retrospectively in humans and needs confirmation through randomized clinical trials before it can change cancer treatment protocols.\",\n  \"what_is_new\": [\n    \"mRNA vaccines delivered directly into tumors can create an inflammatory state that makes checkpoint inhibitors more effective.\",\n    \"Patients who previously received COVID-19 mRNA vaccines showed better survival outcomes when receiving cancer immunotherapy.\",\n    \"The mechanism involves broader tumor antigen presentation on MHC-I molecules and increased type I interferon signaling.\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data comes from a retrospective analysis, not a randomized controlled trial, so confounding factors could explain the results.\",\n    \"The timing of vaccination relative to cancer treatment varied among patients, which could affect outcomes.\",\n    \"Results from mouse models may not fully translate to human cancers due to biological differences.\",\n    \"The patient group had mixed cancer types and treatment histories, making it difficult to draw firm conclusions for specific cancers.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitors\",\n      \"definition\": \"Drugs that block proteins used by cancer cells to evade immune detection, allowing T-cells to attack tumors.\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine using messenger RNA to instruct cells to produce specific proteins that trigger an immune response.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"Major Histocompatibility Complex class I, molecules that display protein fragments on cell surfaces for immune system recognition.\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"Programmed Death-Ligand 1, a protein that suppresses the immune system when it binds to PD-1 on T-cells; targeted by some checkpoint inhibitors.\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"Proteins produced in response to viral infections that activate immune cells and enhance antigen presentation.\"\n    },\n    {\n      \"term\": \"Immunopeptidome\",\n      \"definition\": \"The complete collection of peptides presented by MHC molecules on cell surfaces for immune surveillance.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will the results hold up in prospective randomized clinical trials with standardized vaccination timing?\",\n    \"Which specific cancer types are most likely to benefit from mRNA vaccination combined with checkpoint blockade?\",\n    \"What is the optimal timing and dosing for mRNA vaccination relative to immunotherapy initiation?\",\n    \"Can this approach be extended to other mRNA vaccines beyond SARS-CoV-2 for tumor sensitization?\",\n    \"How durable are the immune responses generated by this combination approach?\"\n  ]\n}\n"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 24,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "list_directory"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-14T12:57:40.104Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-14T12:57:40.582Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-14T12:57:40.582Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-14T12:57:41.776Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-14T12:57:41.776Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-14T12:57:41.776Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-14T12:57:41.776Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-14T12:57:59.820Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-14T12:57:59.820Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-14T12:57:59.820Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-14T12:57:59.820Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "output",
        "timestamp": "2026-02-14T12:58:00.567Z"
      }
    ]
  },
  "grader": {
    "model": "gpt-5.2",
    "value": {
      "verdict": "fail",
      "scores": {
        "faithfulness": 5,
        "coverage": 1,
        "usefulness": 5
      },
      "critical_issues": [
        "The required line-grounding/quoting standard is not met in output/claim_audit.json: multiple evidence \"quotes\" are not present verbatim in the report, and the file is explicitly flagged groundingValid:false with validation errors (C01–C05). This makes the claim audit unreliable for downstream review, even if the associated line references (e.g., L28–L33) point to relevant content.",
        "Several claims in output/claim_audit.json are labeled with overconfident strength (e.g., \"strong\") despite the report framing these as a proposed mechanistic chain and model-dependent effects (L41–L46, L53). The report explicitly notes mechanistic readouts were strongest in specific model systems (L53), which should temper certainty.",
        "Because one of the delivered JSON artifacts (claim_audit.json) fails grounding and introduces non-verbatim evidence text, the overall output set does not satisfy the pass criterion that line references be valid and map cleanly to the numbered report lines."
      ],
      "summary": "study_overview.json and quantitative_findings.json largely track the report’s cohorts, key numbers, and limitations (L14–L23, L28–L33, L48–L53) without inventing new quantitative results, and public_summary.json is generally calibrated with appropriate caution about retrospective human evidence (L49–L52, L55–L56). However, claim_audit.json is not faithfully grounded: it uses synthesized \"quotes\" that do not appear verbatim in the report and is already flagged as grounding-invalid. This breaks a "
    }
  }
}
